Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Tipo de estudo
Intervalo de ano
1.
Medical Principles and Practice. 2010; 19 (5): 344-347
em Inglês | IMEMR | ID: emr-105269

RESUMO

Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin [DHAP] for lymphoma outpatients. Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included. The patients' median age was 32 years [range: 17-61]. Twenty had progressive/refractory disease and 31 relapsed disease. Twenty-five were in clinical stage I/II and 26 in clinical stage III/IV before the initiation of salvage chemotherapy. DHAP consisted of dexamethasone [40 mg i.v. on days 1-4], cytarabine [2 g/m[2] i.v. as 3-hour infusion on days 2 in the evening and 3 in the morning] and cisplatin [35 mg/m[2] as 2-hour infusion on days 1-3] were administered every 21 days. A total of 154 cycles of modified DHAP were administered, with a median of 3 cycles per patient [range: 2-4]. The main toxicity was myelosuppression. WHO grade III-IV neutropenia and grade III-IV thrombocytopenia were observed in 27 [52.9%] and 21 [41%] patients, respectively. The overall response rate [85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma] was 88.3% [39.2% complete response and 49.1% partial response]. The results showed that this outpatient schedule of DHAP was well tolerated and an effective salvage regimen


Assuntos
Humanos , Masculino , Feminino , Doença de Hodgkin/tratamento farmacológico , Dexametasona/administração & dosagem , Linfoma não Hodgkin/tratamento farmacológico , Citarabina/administração & dosagem , /administração & dosagem , Terapia de Salvação , Resultado do Tratamento , Infusões Intravenosas
2.
Medical Principles and Practice. 2009; 18 (1): 73-75
em Inglês | IMEMR | ID: emr-92144

RESUMO

To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associated with renal cell carcinoma. Case Presentation and Intervention: A 59-year-old man presented with muscle weakness and fasciculations in the upper extremities. Neurological examination showed that the fasciculations arose spontaneously in the upper limbs. Electrodiagnostic studies revealed an active neurogenic disorder. The patient was diagnosed with a motor neuron disease mimicking amyotrophic lateral sclerosis. Urine analysis revealed microscopic hematuria. Abdominal computerized tomography scans showed a 9.5 x 8 cm renal mass in the lower pole of the right kidney. Curative right radical nephrectomy was performed. Pathologic examination showed a clear cell adenocarcinoma. After nephrectomy, the muscle weakness and fasciculations disappeared spontaneously within 2 months. The patient was disease-free for 58 months after right radical nephrectomy. He complained of muscle weakness and fasciculation at the last follow-up again. Physical examination revealed fasciculation in the upper limbs. Abdominal tomography showed a 22 x 20 mm solid mass in the lower pole of the left kidney. Kidney-saving surgery was performed and the diagnosis of renal cell carcinoma was confirmed pathologically. Following surgery, fasciculations completely disappeared and muscle weakness diminished within 3 months. This case highlights motor neuron disease as a rare paraneoplastic syndrome in association with renal cell carcinoma and resolution after removal of the tumor


Assuntos
Humanos , Masculino , Doença dos Neurônios Motores/diagnóstico , Esclerose Lateral Amiotrófica/diagnóstico , Carcinoma de Células Renais/diagnóstico , Neoplasias Renais , Debilidade Muscular , Fasciculação , Extremidade Superior , Eletrodiagnóstico , Tomografia Computadorizada por Raios X , Nefrectomia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA